Search

Your search keyword '"Vitetta, Francesca"' showing total 164 results

Search Constraints

Start Over You searched for: Author "Vitetta, Francesca" Remove constraint Author: "Vitetta, Francesca"
164 results on '"Vitetta, Francesca"'

Search Results

1. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients

3. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

4. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

5. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

7. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

10. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

11. Definitive childlessness in women with multiple sclerosis: a multicenter study

12. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band

14. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

19. Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients

20. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

21. Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)

22. Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements.

23. Kappa Index versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders

24. Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia

27. Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis

33. Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients

34. Are novel outcome measures for Charcot–Marie–Tooth disease sensitive to change? The 6-minute walk test and StepWatch™ Activity Monitor in a 12-month longitudinal study

35. Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study

36. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.

38. First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence

39. Systematic assessment and characterization of chronic pain in multiple sclerosis patients

42. Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study

44. Previous treatment influences fingolimod efficacy in relapsing–remitting multiple sclerosis: results from an observational study

45. Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study (P7.216)

46. Natalizumab Discontinuation after the 24 th Course: Which Is Way? The TY-STOP Study (P01.197)

48. Pearls & Oy-sters

Catalog

Books, media, physical & digital resources